Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 965 | 1083 | 965 | 593 | - | - |
Fund Return | -3.47% | 8.34% | -3.47% | -15.97% | - | - |
Place in category | 168 | 164 | 168 | 131 | - | - |
% in Category | 80 | 74 | 80 | 84 | - | - |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
JPI Global Income Fund A div USD he | 17.93B | 9.78 | 2.47 | 4.18 | ||
JPI Global Income Fund A mth USD he | 17.93B | 9.75 | 2.44 | 4.16 | ||
JPI Global Income Fund C acc USD he | 17.93B | 10.32 | 3.13 | 4.86 | ||
JPI Global Income Fund C dist USD h | 17.93B | 10.31 | 3.12 | 4.85 | ||
JPI Global Income Fund C mth USD he | 17.93B | 10.32 | 3.13 | 4.85 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Franklin Biotech Discovery Nacc | 101.15M | 4.88 | -4.60 | 3.64 | ||
Candriam Equities Biotech C USD Cap | 1.41B | 11.83 | 4.94 | 6.48 | ||
LU0133359157 | 1.41B | 11.48 | 4.52 | 6.01 | ||
Equities L Biotechnology Class I US | 1.41B | 12.01 | 4.82 | 6.85 | ||
Equities L Biotechnology Class R US | 1.41B | 12.65 | 5.83 | 7.34 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Alnylam | US02043Q1076 | 3.31 | 244.89 | -0.77% | |
Vertex | US92532F1003 | 3.18 | 450.97 | +0.13% | |
Amgen | US0311621009 | 3.12 | 294.53 | +1.60% | |
Novartis | CH0012005267 | 3.08 | 93.68 | +2.32% | |
Biomarin Pharma | US09061G1013 | 3.04 | 64.26 | +1.28% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Sell | Strong Sell | Strong Sell |
Technical Indicators | Strong Sell | Strong Sell | Strong Sell |
Summary | Strong Sell | Strong Sell | Strong Sell |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review